Literature DB >> 832918

Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase.

A A Yunis, G K Arimura, D J Russin.   

Abstract

An undifferentiated human pancreatic carcinoma has been established in continuous culture and is grown in Dulbecco's modified. Eagle's medium fortified with 10% fetal calf serum and 2.5% horse serum. The established cell line (MIA PaCa-2) has a doubling time of 40 h. The cells are large with abundant cytoplasm, exhibit a high degree of aneuploidy and have a tendency to grow on top of other cells. MIA PaCa-2 grows in soft agar with a colony-forming efficiency of 19%. Both MIA PaCa-2 cells and a cell line from another pancreatic carcinoma obtained from National Cancer Institute (NCI) are sensitive to asparaginase, a property not shared by several other human tumor cell lines tested.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 832918     DOI: 10.1002/ijc.2910190118

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  94 in total

1.  A genome-wide RNAi screen for polypeptides that alter rpS6 phosphorylation.

Authors:  Angela Papageorgiou; Joseph Avruch
Journal:  Methods Mol Biol       Date:  2012

2.  Differential mucin gene expression in human pancreatic and colon cancer cells.

Authors:  S Yonezawa; J C Byrd; R Dahiya; J J Ho; J R Gum; B Griffiths; D M Swallow; Y S Kim
Journal:  Biochem J       Date:  1991-06-15       Impact factor: 3.857

3.  Effects of a histone deacetylase inhibitor, sodium butyrate, on 53-kDa protein expression and sensitivity to anticancer drugs of pancreatic cancer cells.

Authors:  Masaki Kitazono; Hiroyuki Shinchi; Sumiya Ishigami; Shinichi Ueno; Shoji Natsugoe
Journal:  Curr Ther Res Clin Exp       Date:  2010-06

4.  Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase.

Authors:  Nicholas O Roman; Betty K Samulitis; Lee Wisner; Terry H Landowski; Robert T Dorr
Journal:  Cancer Chemother Pharmacol       Date:  2010-03-26       Impact factor: 3.333

5.  Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer.

Authors:  Peter Büchler; Howard A Reber; Mendel M Roth; Mark Shiroishi; Helmut Friess; Oscar J Hines
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

6.  A new human pancreatic carcinoma cell line developed for adoptive immunotherapy studies with lymphokine-activated killer cells in nude mice.

Authors:  B J Drucker; F M Marincola; D Y Siao; T A Donlon; C D Bangs; W D Holder
Journal:  In Vitro Cell Dev Biol       Date:  1988-12

7.  Elaeocarpus reticulatus fruit extracts reduce viability and induce apoptosis in pancreatic cancer cells in vitro.

Authors:  Alexandria Turner; Danielle R Bond; Quan V Vuong; Anita Chalmers; Emma L Beckett; Judith Weidenhofer; Christopher J Scarlett
Journal:  Mol Biol Rep       Date:  2020-02-17       Impact factor: 2.316

8.  Secretion granules of transplantable pancreatic acinar carcinoma of rat.

Authors:  J K Reddy; M K Reddy; L J Hansen; S A Qureshi
Journal:  Biochem J       Date:  1980-06-15       Impact factor: 3.857

9.  A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells.

Authors:  Jianliang Zhang; Di-Hua He; Maria Zajac-Kaye; Steven N Hochwald
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

10.  Generation of an in vitro 3D PDAC stroma rich spheroid model.

Authors:  Matthew J Ware; Vazrik Keshishian; Justin J Law; Jason C Ho; Carlos A Favela; Paul Rees; Billie Smith; Sayeeduddin Mohammad; Rosa F Hwang; Kimal Rajapakshe; Cristian Coarfa; Shixia Huang; Dean P Edwards; Stuart J Corr; Biana Godin; Steven A Curley
Journal:  Biomaterials       Date:  2016-09-02       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.